On-Demand Webinar: Treasure Hunting with Octet® | A New-Wave Biosensor Approach for Direct, Fast and High-Throughput AAV Process Development
Last updated: February 2024
This webinar will highlight REGENXBIO’s experience in finding a high-throughput technology for AAV capsid concentration quantification including comparisons between Octet® AAVX Biosensors and other analytical methods. We will also present an assessment on reliability of % full capsid data generated using various methods including Octet® AAVX Biosensors, as well as case studies making use of the quantification information generated from this technology.
Overview
Gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. While the global pipeline for adeno-associated virus (AAV) gene therapy continues to expand, there are key challenges, such as characterization data to better understand AAV, that still need to be addressed. One of the fundamental characterization datasets that should be assessed, especially in a high-throughput format, is AAV capsid concentration in solution.
- Document type: Webinar
- View time: 53 minutes
Key Takeaways
Topics discussed:
- Reasons explaining why it is necessary to quantify total AAV capsids
- Evaluation summary of different methods for capsid quantification
- Comparison data package for calculated % full capsid using Octet® data and other methods
- Real life datasets showing the usefulness of the capsid titer data and packaging efficiency (%full) data generated on Octet® BLI Platform
Webinar Speakers
Amanda Zhang, MS
Senior Scientist Scientific Project Manager
REGENXBIO
Amanda Zhang is a Senior Scientist and Scientific Project Manager with REGENXBIO who has been in the downstream field working on purification and characterization of antibodies and adeno-associated virus (AAV) for 15 years.
She has developed numerous downstream processes that led to IND filings and has set up technologies for the early characterizations of antibodies and AAV. At REGENXBIO, she is responsible for production of recombinant AAV vectors in support of pre-clinical and IND enabling studies.
In addition, she plays a key role in bridging R&ED and Process Development functions by providing early phase knowledge on process, product, and manufacturability to relevant teams. She also takes part in facilitating and streamlining operations to maximize impact on early phase pipeline and platform development.
